206 related articles for article (PubMed ID: 34138876)
21. Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials.
Mosquera C; Maglic D; Zervos EE
Cancer Genet; 2016 Dec; 209(12):567-581. PubMed ID: 27613577
[TBL] [Abstract][Full Text] [Related]
22. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis.
Corcoran RB; Contino G; Deshpande V; Tzatsos A; Conrad C; Benes CH; Levy DE; Settleman J; Engelman JA; Bardeesy N
Cancer Res; 2011 Jul; 71(14):5020-9. PubMed ID: 21586612
[TBL] [Abstract][Full Text] [Related]
23. [The value of chemoradiotherapy in the management of locally advanced pancreatic adenocarcinoma: systematic review].
Azria D; Seblain-El-Guerche C; Girard N; Hennequin C; Huguet F
Bull Cancer; 2008 Nov; 95(11):1116-30. PubMed ID: 19036684
[TBL] [Abstract][Full Text] [Related]
24. BRM/SMARCA2 promotes the proliferation and chemoresistance of pancreatic cancer cells by targeting JAK2/STAT3 signaling.
Zhang Z; Wang F; Du C; Guo H; Ma L; Liu X; Kornmann M; Tian X; Yang Y
Cancer Lett; 2017 Aug; 402():213-224. PubMed ID: 28602977
[TBL] [Abstract][Full Text] [Related]
25. Promising new therapies in advanced pancreatic adenocarcinomas.
Kundranda M; Kachaamy T
Future Oncol; 2014 Dec; 10(16):2629-41. PubMed ID: 25531049
[TBL] [Abstract][Full Text] [Related]
26. Expression of phosphorylated estrogen receptor beta is an independent negative prognostic factor for pancreatic ductal adenocarcinoma.
Pozios I; Knösel T; Zhao Y; Assmann G; Pozios I; Müller MH; Bruns CJ; Kreis ME; Seeliger H
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1887-1897. PubMed ID: 30046904
[TBL] [Abstract][Full Text] [Related]
27. Emerging antibodies for the treatment of pancreatic cancer.
Andrikou K; Peterle C; Pipitone S; Salati M; Cascinu S
Expert Opin Emerg Drugs; 2017 Mar; 22(1):39-51. PubMed ID: 28253833
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
Xu BQ; Fu ZG; Meng Y; Wu XQ; Wu B; Xu L; Jiang JL; Li L; Chen ZN
Oncotarget; 2016 Sep; 7(38):62177-62193. PubMed ID: 27556697
[TBL] [Abstract][Full Text] [Related]
29. Molecular changes in pancreatic cancer: implications for molecular targeting therapy.
Demetter P; Maréchal R; Verset L; Salmon I; Bachet JB; Van Laethem JL
Acta Gastroenterol Belg; 2012 Jun; 75(2):210-4. PubMed ID: 22870784
[TBL] [Abstract][Full Text] [Related]
30. Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway.
Fang Z; Jung KH; Yan HH; Kim SJ; Rumman M; Park JH; Han B; Lee JE; Kang YW; Lim JH; Hong SS
Cell Physiol Biochem; 2018; 47(5):1751-1768. PubMed ID: 29953970
[TBL] [Abstract][Full Text] [Related]
31. Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer.
Gong J; Xie J; Bedolla R; Rivas P; Chakravarthy D; Freeman JW; Reddick R; Kopetz S; Peterson A; Wang H; Fischer SM; Kumar AP
Clin Cancer Res; 2014 Mar; 20(5):1259-73. PubMed ID: 24520096
[TBL] [Abstract][Full Text] [Related]
32. Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma.
Miller A; McLeod L; Alhayyani S; Szczepny A; Watkins DN; Chen W; Enriori P; Ferlin W; Ruwanpura S; Jenkins BJ
Oncogene; 2017 May; 36(21):3059-3066. PubMed ID: 27893707
[TBL] [Abstract][Full Text] [Related]
33. Epidermal Growth Factor Receptor and Its Role in Pancreatic Cancer Treatment Mediated by Nanoparticles.
Grapa CM; Mocan T; Gonciar D; Zdrehus C; Mosteanu O; Pop T; Mocan L
Int J Nanomedicine; 2019; 14():9693-9706. PubMed ID: 31849462
[TBL] [Abstract][Full Text] [Related]
34. 1-Methyl-D-tryptophan Reduces Tumor CD133
Alahdal M; Xing Y; Tang T; Liang J
Sci Rep; 2018 Jun; 8(1):9869. PubMed ID: 29959375
[TBL] [Abstract][Full Text] [Related]
35. Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis.
Lu Z; Weniger M; Jiang K; Boeck S; Zhang K; Bazhin A; Miao Y; Werner J; D'Haese JG
Target Oncol; 2018 Aug; 13(4):447-459. PubMed ID: 30062609
[TBL] [Abstract][Full Text] [Related]
36. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.
Christenson ES; Jaffee E; Azad NS
Lancet Oncol; 2020 Mar; 21(3):e135-e145. PubMed ID: 32135117
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-301a promotes pancreatic cancer invasion and metastasis through the JAK/STAT3 signaling pathway by targeting SOCS5.
Hu H; Zhang Q; Chen W; Wu T; Liu S; Li X; Luo B; Zhang T; Yan G; Lu H; Lu Z
Carcinogenesis; 2020 Jun; 41(4):502-514. PubMed ID: 31233116
[TBL] [Abstract][Full Text] [Related]
38. Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease.
Gromisch C; Qadan M; Machado MA; Liu K; Colson Y; Grinstaff MW
Cancer Res; 2020 Aug; 80(16):3179-3192. PubMed ID: 32220831
[TBL] [Abstract][Full Text] [Related]
39. EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.
Singh A; Xu J; Mattheolabakis G; Amiji M
Nanomedicine; 2016 Apr; 12(3):589-600. PubMed ID: 26656632
[TBL] [Abstract][Full Text] [Related]
40. Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human Pancreatic Cancer Cells.
Chen X; Tian J; Su GH; Lin J
Curr Cancer Drug Targets; 2019; 19(5):417-427. PubMed ID: 29714141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
